Charles Schwab’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $190M | Sell |
1,268,587
-183,216
| -13% | -$19.9M | 0.03% | 480 |
|
|
2026
Q1 | $134M | Sell |
1,451,803
-5,873
| -0.4% | -$590K | 0.02% | 586 |
|
|
2025
Q4 | $149M | Buy |
1,457,676
+41,792
| +3% | +$3.74M | 0.02% | 531 |
|
|
2025
Q3 | $88.5M | Buy |
1,415,884
+402,612
| +40% | +$21.9M | 0.01% | 789 |
|
|
2025
Q2 | $52.7M | Buy |
1,013,272
+16,766
| +2% | +$749K | 0.01% | 1072 |
|
|
2025
Q1 | $42.5M | Sell |
996,506
-20,027
| -2% | -$864K | 0.01% | 1185 |
|
|
2024
Q4 | $31.1M | Buy |
1,016,533
+13,395
| +1% | +$377K | 0.01% | 1434 |
|
|
2024
Q3 | $23M | Sell |
1,003,138
-306,293
| -23% | -$8.67M | ﹤0.01% | 1622 |
|
|
2024
Q2 | $37.8M | Buy |
1,309,431
+32,332
| +3% | +$753K | 0.01% | 1265 |
|
|
2024
Q1 | $26.3M | Buy |
1,277,099
+44,982
| +4% | +$964K | 0.01% | 1450 |
|
|
2023
Q4 | $33.3M | Buy |
1,232,117
+20,618
| +2% | +$541K | 0.01% | 1271 |
|
|
2023
Q3 | $35.9M | Buy |
1,211,499
+292,888
| +32% | +$10.3M | 0.01% | 1127 |
|
|
2023
Q2 | $32.9M | Buy |
918,611
+312,875
| +52% | +$8.99M | 0.01% | 1164 |
|
|
2023
Q1 | $14.2M | Buy |
605,736
+5,254
| +0.9% | +$150K | ﹤0.01% | 1699 |
|
|
2022
Q4 | $16.3M | Buy |
600,482
+23,713
| +4% | +$1.09M | 0.01% | 1573 |
|
|
2022
Q3 | $31M | Buy |
576,769
+8,084
| +1% | +$415K | 0.01% | 1074 |
|
|
2022
Q2 | $22.9M | Buy |
568,685
+11,652
| +2% | +$577K | 0.01% | 1294 |
|
|
2022
Q1 | $36.9M | Buy |
557,033
+12,600
| +2% | +$862K | 0.01% | 1083 |
|
|
2021
Q4 | $54.5M | Buy |
544,433
+13,450
| +3% | +$1.39M | 0.02% | 837 |
|
|
2021
Q3 | $66.4M | Buy |
530,983
+93,306
| +21% | +$11.1M | 0.02% | 702 |
|
|
2021
Q2 | $54.4M | Buy |
437,677
+14,293
| +3% | +$1.92M | 0.02% | 802 |
|
|
2021
Q1 | $64.6M | Buy |
423,384
+2,672
| +0.6% | +$404K | 0.02% | 674 |
|
|
2020
Q4 | $54.2M | Buy |
420,712
+40,959
| +11% | +$4.71M | 0.02% | 733 |
|
|
2020
Q3 | $42.4M | Buy |
379,753
+125,620
| +49% | +$11.5M | 0.02% | 739 |
|
|
2020
Q2 | $20.6M | Buy |
254,133
+62,145
| +32% | +$5.01M | 0.01% | 1144 |
|
|
2020
Q1 | $13.4M | Buy |
191,988
+17,998
| +10% | +$1.38M | 0.01% | 1274 |
|
|
2019
Q4 | $13.6M | Buy |
173,990
+3,850
| +2% | +$277K | 0.01% | 1478 |
|
|
2019
Q3 | $10.9M | Buy |
170,140
+24,214
| +17% | +$2.13M | 0.01% | 1558 |
|
|
2019
Q2 | $12.6M | Buy |
145,926
+69,363
| +91% | +$5.3M | 0.01% | 1446 |
|
|
2019
Q1 | $5.87M | Buy |
76,563
+2,465
| +3% | +$137K | ﹤0.01% | 1907 |
|
|
2018
Q4 | $2.79M | Buy |
+74,098
| New | +$2.73M | ﹤0.01% | 2202 |
|
Other funds holding GH
DTC
Charles Schwab's GH Position: Q2 2026 in Review
Charles Schwab reduced its Guardant Health (GH) stake by 13% in Q2 2026, selling an estimated $19.9M and leaving 1,268,587 shares worth $190M. The position accounts for 0.03% of the portfolio, ranked #480.
Charles Schwab first reported a position in GH in Q4 2018 and has held it in 31 quarters since. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.
- Charles Schwab held 1,268,587 shares of Guardant Health worth $190M as of Q2 2026.
- Charles Schwab sold 183,216 Guardant Health shares in Q2 2026, an estimated $19.9M.
- Guardant Health made up 0.03% of Charles Schwab's portfolio in Q2 2026, its #480 holding.
- Charles Schwab first reported a position in Guardant Health in Q4 2018 and has held it in 31 quarters since.
- 597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.